{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:12:37Z","timestamp":1791655957618,"version":"4.3.4"},"reference-count":53,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cephalalgia"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cluster headache (CH) is one of the most severe types of pain, yet pharmacological treatment options are limited. In the present study, we aimed to systematically evaluate the effect of treatment with monoclonal antibodies (mAbs) blocking calcitonin gene-related peptide (CGRP) in the prevention of episodic cluster headache (eCH) and chronic (cCH) cluster headache.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched Embase, Medline, Cochrane CENTRAL and Web of Science. Included were all clinical trials, case series and single case reports that reported the effects of anti-CGRP treatment on CH. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) were used for abstracting data. Risk of bias was evaluated using the Risk of Bias 2 (RoB 2) tool for randomized trials and Risk Of Bias In Non-randomized Studies \u2013 of Interventions (ROBINS-I) for non-randomized studies. The collected data from all studies were summarized using descriptive statistics. Data from randomized trials were additionally reported as odds ratio (OR) with 95% confidence interval (CI) using a random-effects meta-analysis. Given the variability in study design and the diverse formats of reported outcome data, we primarily focused on the \u2265\u200950% responder rate reported closest to the 4-week point following drug administration, which was consistently reported in almost all studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      From 734 identified records, 25 articles were included, comprising a total of 1587 patients. Meta-analysis of randomized, placebo-controlled trials suggests that anti-CGRP treatment had a statistically significant positive effect in eCH (OR\u2009=\u20091.65, 95% CI\u2009=\u20091.07\u20132.55,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.02), with galcanezumab 300\u2005mg and eptinezumab 400\u2005mg being more effective than placebo in achieving a \u2265\u200950% responder rate in eCH attacks at the 4-week mark following administration. Simultaneously, a significant mean reduction in weekly attack frequency at week 4 was observed only for galcanezumab 300\u2005mg (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.04). Despite findings from some non-randomized trials, the meta-analysis showed no statistically significant effect in cCH (OR\u2009=\u20091.07, 95% CI\u2009=\u20090.78\u20131.48,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.68).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our analysis revealed a beneficial effect of anti-CGRP mAbs in eCH, while no effect was observed in cCH. Despite these positive findings, the favourable results with galcanezumab and eptinezumab in eCH should be interpreted with caution due to discrepancies in the outcome data and the challenges associated with selecting endpoints in CH trials. The discrepancy between real-world data and findings from controlled trials further highlights the need for continued discussions among experts to develop more adequate methods for conducting CH trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>PROSPERO ID: CRD420250609351.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03331024261434209","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T16:00:20Z","timestamp":1775836820000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and effectiveness of anti-CGRP monoclonal antibodies treatment in the prevention of cluster headache attacks: A systematic review and meta-analysis"],"prefix":"10.1177","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-0462-2047","authenticated-orcid":false,"given":"Lukasz","family":"Kolakowski","sequence":"first","affiliation":[{"name":"University Hospital Zurich"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2502-7102","authenticated-orcid":false,"given":"Marie Therese","family":"Kleinsorge","sequence":"additional","affiliation":[{"name":"University Hospital Zurich"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Wegener","sequence":"additional","affiliation":[{"name":"University Hospital Zurich"},{"name":"University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2778-6790","authenticated-orcid":false,"given":"Heiko","family":"Pohl","sequence":"additional","affiliation":[{"name":"University Hospital Zurich"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199108013250505"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/117.3.427"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410280213"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420949858"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420905321"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813440"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2015.09.2938"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3501"},{"key":"e_1_3_2_10_2","first-page":"48","article-title":"Calcitonin gene-related peptide monoclonal antibodies: key lessons from real-world evidence","volume":"14","author":"Orlando B","unstructured":"Orlando B, Egeo G, Aurilia C, et al. Calcitonin gene-related peptide monoclonal antibodies: key lessons from real-world evidence. Brain Sci 2024 Sep 22; 14: 48.","journal-title":"Brain Sci"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.081879"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413485658"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/03331024221103509"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1080\/01616412.2024.2440022"},{"key":"e_1_3_2_18_2","unstructured":"NCT02945046: A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Episodic Cluster Headache (ECH). Available from: https:\/\/clinicaltrials.gov\/study\/NCT02945046. accessed Nov 2025"},{"key":"e_1_3_2_19_2","unstructured":"NCT02964338: A Study Comparing the Efficacy and Safety of Fremanezumab (TEV-48125) for the Prevention of Chronic Cluster Headache (CCH). Available from: https:\/\/clinicaltrials.gov\/study\/NCT02964338. accessed Nov 2025"},{"key":"e_1_3_2_20_2","article-title":"Erenumab for chronic cluster headache: a randomized clinical trial","volume":"8","author":"Mecklenburg J","unstructured":"Mecklenburg J, Gaul C, Fitzek M, et al. Erenumab for chronic cluster headache: a randomized clinical trial. JAMA Netw Open 2025 Jun 2; 8: e2516318.","journal-title":"JAMA Netw Open"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2025.1317"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurop.2022.08.003"},{"key":"e_1_3_2_23_2","first-page":"36","article-title":"Preventive therapy with galcanezumab for two consecutive cluster bouts in patients with episodic cluster headache: an observational multicenter study","volume":"24","author":"Hong Y","unstructured":"Hong Y, Kang MK, Moon HS, et al. Preventive therapy with galcanezumab for two consecutive cluster bouts in patients with episodic cluster headache: an observational multicenter study. J Headache Pain 2023 Oct 10; 24: 36.","journal-title":"J Headache Pain"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-021-05624-1"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1080\/17581869.2024.2427564"},{"key":"e_1_3_2_26_2","first-page":"11","article-title":"Cluster headache and galcanezumab: the first real-world Brazilian study and an expert consensus on its use among other treatments","volume":"25","author":"Krymchantowski A","unstructured":"Krymchantowski A, Jevoux C, Piovesan \u00c9J, et al. Cluster headache and galcanezumab: the first real-world Brazilian study and an expert consensus on its use among other treatments. J Headache Pain 2024 Dec 3; 25: 11.","journal-title":"J Headache Pain"},{"key":"e_1_3_2_27_2","first-page":"333102423122618","article-title":"Efficacy and safety of galcanezumab as chronic cluster headache preventive treatment under real world conditions: observational prospective study","volume":"44","author":"Lamas P\u00e9rez R","unstructured":"Lamas P\u00e9rez R, Mill\u00e1n-V\u00e1zquez M, Gonz\u00e1lez-Oria C. Efficacy and safety of galcanezumab as chronic cluster headache preventive treatment under real world conditions: observational prospective study. Cephalalgia 2024 Mar; 44: 3331024231226181.","journal-title":"Cephalalgia"},{"key":"e_1_3_2_28_2","first-page":"32","article-title":"Real-world experience with 240mg of galcanezumab for the preventive treatment of cluster headache","volume":"23","author":"Mo H","unstructured":"Mo H, Kim BK, Moon HS, et al. Real-world experience with 240mg of galcanezumab for the preventive treatment of cluster headache. J Headache Pain 2022 Oct 8; 23: 32.","journal-title":"J Headache Pain"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(25)00065-1"},{"key":"e_1_3_2_30_2","first-page":"128","article-title":"Galcanezumab effective for chronic refractory cluster headaches: a case report","volume":"61","author":"Fahimi G","year":"2021","unstructured":"Fahimi G, Joseph R. Galcanezumab effective for chronic refractory cluster headaches: a case report. Headache 2021; 61: 128\u2013129.","journal-title":"Headache"},{"key":"e_1_3_2_31_2","first-page":"103","article-title":"CGRP Monoclonal antibodies off-label use in patients with hemicrania continua and chronic cluster headache","volume":"22","author":"Vashchenko N","unstructured":"Vashchenko N, Skorobogatykh K, Azimova J. CGRP Monoclonal antibodies off-label use in patients with hemicrania continua and chronic cluster headache. J Headache Pain. 2021 Sep 7; 22: 103.","journal-title":"J Headache Pain."},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.3390\/neurolint15010020"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-024-07708-0"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.14404"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2023.12.008"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1177\/2515816320947713"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420949866"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.13832"},{"key":"e_1_3_2_39_2","first-page":"590","article-title":"Fremanezumab in the cluster headache treatment","volume":"29","author":"Uzhakhov AV","year":"2022","unstructured":"Uzhakhov AV, Korobkova N, Skorobogatykh D, et al. Fremanezumab in the cluster headache treatment. Euro J Neurol 2022; 29: 590\u2013590.","journal-title":"Euro J Neurol"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.14234"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20143527"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-022-01070-6"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-29821995.1506452.x"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.14292"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102409351754"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2003.00531.x"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2002.02028.x"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awf118"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000055902.23139.16"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.1675"},{"key":"e_1_3_2_51_2","first-page":"333102423122397","article-title":"Reduced plasma calcitonin gene-related peptide level identified in cluster headache: a prospective and controlled study","volume":"44","author":"Petersen AS","unstructured":"Petersen AS, Lund N, Me\u00dflinger K, et al. Reduced plasma calcitonin gene-related peptide level identified in cluster headache: a prospective and controlled study. Cephalalgia 2024 Mar; 44: 3331024231223970.","journal-title":"Cephalalgia"},{"key":"e_1_3_2_52_2","first-page":"333102423115936","article-title":"Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: a systematic review and network meta-analysis of phase 3 randomised controlled trials","volume":"43","author":"Haghdoost F","unstructured":"Haghdoost F, Puledda F, Garcia-Azorin D, et al. Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: a systematic review and network meta-analysis of phase 3 randomised controlled trials. Cephalalgia 2023 Apr; 43: 3331024231159366.","journal-title":"Cephalalgia"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.3859"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00482-022-00648-8"}],"container-title":["Cephalalgia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024261434209","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03331024261434209","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024261434209","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:44:24Z","timestamp":1777387464000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03331024261434209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1177\/03331024261434209"],"URL":"https:\/\/doi.org\/10.1177\/03331024261434209","relation":{},"ISSN":["0333-1024","1468-2982"],"issn-type":[{"value":"0333-1024","type":"print"},{"value":"1468-2982","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"article-number":"03331024261434209"}}